DIVISLAB2024-07-012024-09-30 DIVISLAB2024-07-012024-09-30 DIVISLAB2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member DIVISLAB2024-09-30 DIVISLAB2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2024-04-01 2025-03-31 2024-11-09 2024-10-29 INR Crores Half yearly 11:15:00 12:25:00 2024-11-09 2024-11-09 true Cash Flow Indirect Not applicable Single segment Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients. 2024-07-01 2024-09-30 Unaudited Consolidated 23380000000.00 1060000000.00 24440000000.00 9760000000.00 0.00 -70000000.00 3040000000.00 10000000.00 990000000.00 3490000000.00 17220000000.00 7220000000.00 0.00 7220000000.00 2180000000.00 -60000000.00 2120000000.00 0.00 5100000000.00 0.00 0.00 0.00 0.00 5100000000.00 10000000.00 5110000000.00 5100000000.00 0.00 5110000000.00 0.00 530000000.00 2 19.20 19.20 0.00 0.00 19.20 19.20 1. The above Statement of consolidated unaudited financial results for the quarter and half year ended 30th September, 2024, Statement of consolidated unaudited assets and liabilities as at 30th September, 2024 and Statement of consolidated unaudited cash flows for the half year ended 30th September, 2024 (‘Consolidated Statements’) are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. These consolidated Statements are as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 9th November,2024. The statutory auditors have carried out a limited review of the consolidated statements and issued an unmodified report thereon. 2. The consolidated unaudited financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”) 3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. 5. Details of Forex gain/(loss) are as given below. (Rs. in Crores) Quarter ended Half Year ended Year ended 30.09.2024 30.06.2024 30.09.2023 30.09.2024 30.09.2023 31.03.2024 Forex gain/(loss) 29 (1) 11 28 14 30 Forex gain has been included in other income and loss has been included in other expenses. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 44560000000.00 1840000000.00 46400000000.00 18690000000.00 0.00 -470000000.00 5960000000.00 10000000.00 1960000000.00 6990000000.00 33140000000.00 13260000000.00 0.00 13260000000.00 3970000000.00 -110000000.00 3860000000.00 0.00 9400000000.00 0.00 0.00 0.00 0.00 9400000000.00 20000000.00 9420000000.00 9400000000.00 0.00 9420000000.00 0.00 530000000.00 2 35.40 35.40 0.00 0.00 35.40 35.40 Other Expenses 3490000000.00 Other Expenses 6990000000.00 46520000000.00 13160000000.00 0.00 60000000.00 850000000.00 0.00 620000000.00 1470000000.00 150000000.00 1090000000.00 62450000000.00 31450000000.00 0.00 21810000000.00 380000000.00 35640000000.00 0.00 60000000.00 57890000000.00 4070000000.00 93410000000.00 155860000000.00 530000000.00 136640000000.00 137170000000.00 137170000000.00 0.00 20000000.00 20000000.00 0.00 5760000000.00 5780000000.00 50000000.00 8550000000.00 660000000.00 9260000000.00 2490000000.00 480000000.00 680000000.00 12910000000.00 18690000000.00 155860000000.00 10000000.00 390000000.00 -30000000.00 0.00 -660000000.00 0.00 -60000000.00 10000000.00 0.00 320000000.00 0.00 -630000000.00 0.00 1960000000.00 0.00 0.00 0.00 30000000.00 0.00 -110000000.00 0.00 1520000000.00 0.00 -30000000.00 0.00 0.00 0.00 40000000.00 0.00 -280000000.00 12980000000.00 0.00 0.00 0.00 3720000000.00 0.00 9260000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6640000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1520000000.00 0.00 530000000.00 0.00 -4590000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50000000.00 0.00 0.00 0.00 7960000000.00 10000000.00 0.00 0.00 -7920000000.00 -3250000000.00 0.00 -3250000000.00 3630000000.00 380000000.00 Gain/(Loss) on Remeasurement of post-employment benefit obligations 0.00 Gain/(Loss) on Remeasurement of post-employment benefit obligations -10000000.00 0.00 -10000000.00 0.00 0.00 Gain on exchange differences in translating the financial statements of foreign operations 20000000.00 Gain on exchange differences in translating the financial statements of foreign operations 40000000.00 20000000.00 40000000.00 10000000.00 10000000.00